<DOC>
	<DOC>NCT02708576</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of NGM313, both single dose and multiple doses, in normal healthy overweight and obese adult participants.</brief_summary>
	<brief_title>Phase 1 Study of NGM313 in Healthy Adult Participants</brief_title>
	<detailed_description />
	<criteria>BMI range 2740 kg/m2, inclusive for the SAD module, and 2740 kg/m2, inclusive for the MAD module; Normal clinical laboratory evaluations Normal ECG findings Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder Uncontrolled hypertension defined as sitting blood pressure systolic &gt; 150 mm/Hg and/or diastolic &gt; 90 mm/Hg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>